Zoltán Husti
University of Szeged
Network
Latest external collaboration on country level. Dive into details by clicking on the dots.
Publication
Featured researches published by Zoltán Husti.
American Journal of Physiology-heart and Circulatory Physiology | 2010
Esther Pueyo; Zoltán Husti; Tibor Hornyik; István Baczkó; Pablo Laguna; András Varró; Blanca Rodriguez
Protracted QT interval (QTI) adaptation to abrupt heart rate (HR) changes has been identified as a clinical arrhythmic risk marker. This study investigates the ionic mechanisms of QTI rate adaptation and its relationship to arrhythmic risk. Computer simulations and experimental recordings in human and canine ventricular tissue were used to investigate the ionic basis of QTI and action potential duration (APD) to abrupt changes in HR with a protocol commonly used in clinical studies. The time for 90% QTI adaptation is 3.5 min in simulations, in agreement with experimental and clinical data in humans. APD adaptation follows similar dynamics, being faster in mid-myocardial cells (2.5 min) than in endocardial and epicardial cells (3.5 min). Both QTI and APD adapt in two phases following an abrupt HR change: a fast initial phase with time constant < 30 s, mainly related to L-type calcium and slow-delayed rectifier potassium current, and a second slow phase of >2 min driven by intracellular sodium concentration ([Na(+)](i)) dynamics. Alterations in [Na(+)](i) dynamics due to Na(+)/K(+) pump current inhibition result in protracted rate adaptation and are associated with increased proarrhythmic risk, as indicated by action potential triangulation and faster L-type calcium current recovery from inactivation, leading to the formation of early afterdepolarizations. In conclusion, this study suggests that protracted QTI adaptation could be an indicator of altered [Na(+)](i) dynamics following Na(+)/K(+) pump inhibition as it occurs in patients with ischemia or heart failure. An increased risk of cardiac arrhythmias in patients with protracted rate adaptation may be due to an increased risk of early after-depolarization formation.
European Journal of Pharmacology | 2011
Tamás Szél; István Koncz; Norbert Jost; István Baczkó; Zoltán Husti; László Virág; Alexandra Bussek; Erich Wettwer; Ursula Ravens; Julius Gy. Papp; András Varró
The aim of this study was to investigate the cellular electrophysiological effects of ranolazine on action potential characteristics. The experiments were carried out in dog and human cardiac preparations using the conventional microelectrode technique. In dog Purkinje fibres ranolazine produced a concentration- and frequency-dependent depression of the maximum rate of depolarization (V(max)) while action potential duration (APD) was shortened. In dog and human right ventricular papillary muscle ranolazine exerted no significant effect on APD, while it produced, like mexiletine, use-dependent depression of V(max) with relatively fast onset and offset kinetics. In dog midmyocardial preparations the drug did not exert statistically significant effect on repolarization at 10 μM, although a tendency toward prolongation was observed at 20 μM. A moderate lengthening of APD(90) by ranolazine was noticed in canine atrial preparations obtained from dogs in sinus rhythm and in tachypacing induced remodelled preparations. Use-dependent depression of V(max) was more pronounced in atria from dogs in sinus rhythm than those in remodelled atria or in the ventricle. These findings indicate that ranolazine, in addition to its known late sodium current blocking effect, also depresses peak I(Na) with class I/B antiarrhythmic characteristics. Although peak I(Na) inhibition by ranolazine is stronger in the atria, it is also substantial (at fast stimulation frequencies) in ventricular preparations. Ranolazine also decreased the dispersion of ventricular repolarization (the difference in APD(90) values between Purkinje fibres and papillary muscles), which can contribute to the antiarrhythmic property of the drug.
Current Medicinal Chemistry | 2011
István Baczkó; Zoltán Husti; V. Lang; István Leprán; Peter E. Light
Cardiac atrial and ventricular arrhythmias are major causes of mortality and morbidity. Ischemic heart disease is the most common cause underlying 1) the development of ventricular fibrillation that results in sudden cardiac death and 2) atrial fibrillation that can lead to heart failure and stroke. Current pharmacological agents for the treatment of ventricular and atrial arrhythmias exhibit limited effectiveness and many of these agents can cause serious adverse effects - including the provocation of lethal ventricular arrhythmias. Sarcolemmal ATP-sensitive potassium channels (sarcKATP) couple cellular metabolism to membrane excitability in a wide range of tissues. In the heart, sarcKATP are activated during metabolic stress including myocardial ischemia, and both the opening of sarcKATP and mitochondrial KATP channels protect the ischemic myocardium via distinct mechanisms. Myocardial ischemia leads to a series of events that promote the generation of arrhythmia substrate eventually resulting in the development of life-threatening arrhythmias. In this review, the possible mechanisms of the anti- and proarrhythmic effects of sarcKATP modulation as well as the influence of pharmacological KATP modulators are discussed. It is concluded that in spite of the significant advances made in this field, the possible cardiovascular therapeutic utility of current sarcKATP channel modulators is still hampered by the lack of chamber-specific selectivity. However, recent insights into the chamber-specific differences in the molecular composition of sarcKATP in addition to already existing cardioselective sarcKATP channel modulators with sarcKATP isoform selectivity holds the promise for the future development of pharmacological strategies specific for a variety of atrial and ventricular arrhythmias.
British Journal of Pharmacology | 2014
István Baczkó; David Liknes; Wei Yang; Kevin S.C. Hamming; Gavin J. Searle; Kristian Jaeger; Zoltán Husti; Viktor Juhász; Gergely Klausz; Róbert Pap; László Sághy; András Varró; Vernon W. Dolinsky; Shaohua Wang; Vivek Rauniyar; Dennis G. Hall; Jason R. B. Dyck; Peter E. Light
Atrial fibrillation (AF) is the most common cardiac arrhythmia and is associated with an increased risk for stroke, heart failure and cardiovascular‐related mortality. Candidate targets for anti‐AF drugs include a potassium channel Kv1.5, and the ionic currents IKACh and late INa, along with increased oxidative stress and activation of NFAT‐mediated gene transcription. As pharmacological management of AF is currently suboptimal, we have designed and characterized a multifunctional small molecule, compound 1 (C1), to target these ion channels and pathways.
Canadian Journal of Physiology and Pharmacology | 2015
Zoltán Husti; Katalin Tábori; Viktor Juhász; Tibor Hornyik; András Varró; István Baczkó
A reliable assessment of the pro-arrhythmic potential for drugs in the development phase remains elusive. Rabbits and dogs are commonly used to create models of pro-arrhythmia, but the differences between them with respect to repolarizing potassium currents are poorly understood. We investigated the incidence of drug-induced torsades de pointes (TdP) and measured conventional ECG parameters and the short-term variability of the QT interval (STVQT) following combined pharmacological inhibition of IK1+IKs and IK1+IKr in conscious dogs and anesthetized rabbits. A high incidence of TdP was observed following the combined inhibition of IK1+IKs in dogs (67% vs. 14% in rabbits). Rabbits exhibited higher TdP incidence after inhibition of IK1+IKr (72% vs. 14% in dogs). Increased TdP incidence was associated with significantly larger STVQT in both models. The relatively different roles of IK1 and IKs in dog and rabbit repolarization reserve should be taken into account when extrapolating the results from animal models of pro-arrhythmia to humans. A stronger repolarization reserve in dogs (likely due to stronger IK1 and IKs), and the more human-like susceptibility to arrhythmia of rabbits argues for the preferred use of rabbits in the evaluation of adverse pro-arrhythmic effects.
PLOS ONE | 2012
Attila Kristóf; Zoltán Husti; István Koncz; Zsófia Kohajda; Tamás Szél; Viktor Juhász; Péter Biliczki; Norbert Jost; István Baczkó; Julius Gy. Papp; András Varró; László Virág
Background The aim of the present work was to characterize the electrophysiological effects of the non-steroidal anti-inflammatory drug diclofenac and to study the possible proarrhythmic potency of the drug in ventricular muscle. Methods Ion currents were recorded using voltage clamp technique in canine single ventricular cells and action potentials were obtained from canine ventricular preparations using microelectrodes. The proarrhythmic potency of the drug was investigated in an anaesthetized rabbit proarrhythmia model. Results Action potentials were slightly lengthened in ventricular muscle but were shortened in Purkinje fibers by diclofenac (20 µM). The maximum upstroke velocity was decreased in both preparations. Larger repolarization prolongation was observed when repolarization reserve was impaired by previous BaCl2 application. Diclofenac (3 mg/kg) did not prolong while dofetilide (25 µg/kg) significantly lengthened the QTc interval in anaesthetized rabbits. The addition of diclofenac following reduction of repolarization reserve by dofetilide further prolonged QTc. Diclofenac alone did not induce Torsades de Pointes ventricular tachycardia (TdP) while TdP incidence following dofetilide was 20%. However, the combination of diclofenac and dofetilide significantly increased TdP incidence (62%). In single ventricular cells diclofenac (30 µM) decreased the amplitude of rapid (IKr) and slow (IKs) delayed rectifier currents thereby attenuating repolarization reserve. L-type calcium current (ICa) was slightly diminished, but the transient outward (Ito) and inward rectifier (IK1) potassium currents were not influenced. Conclusions Diclofenac at therapeutic concentrations and even at high dose does not prolong repolarization markedly and does not increase the risk of arrhythmia in normal heart. However, high dose diclofenac treatment may lengthen repolarization and enhance proarrhythmic risk in hearts with reduced repolarization reserve.
Canadian Journal of Physiology and Pharmacology | 2018
Viktor Juhász; Tibor Hornyik; Attila Benák; Norbert Nagy; Zoltán Husti; Róbert Pap; László Sághy; László Virág; András Varró; István Baczkó
Atrial fibrillation (AF) is the most common sustained cardiac arrhythmia and a major cause of morbidity and mortality. Traditional antiarrhythmic agents used for restoration of sinus rhythm have limited efficacy in long-term AF and they may possess ventricular proarrhythmic adverse effects, especially in patients with structural heart disease. The acetylcholine receptor-activated potassium channel (IK,ACh) represents an atrial selective target for future AF management. We investigated the effects of the IK,ACh blocker tertiapin-Q (TQ), a derivative of the honeybee toxin tertiapin, on chronic atrial tachypacing-induced AF in conscious dogs, without the influence of anesthetics that modulate a number of cardiac ion channels. Action potentials (APs) were recorded from right atrial trabeculae isolated from dogs with AF. TQ significantly and dose-dependently reduced AF incidence and AF episode duration, prolonged atrial effective refractory period, and prolonged AP duration. The reference drugs propafenone and dofetilide, both used in the clinical management of AF, exerted similar effects against AF in vivo. Dofetilide prolonged atrial AP duration, whereas propafenone increased atrial conduction time. TQ and propafenone did not affect the QT interval, whereas dofetilide prolonged the QT interval. Our results show that inhibition of IK,ACh may represent a novel, atrial-specific target for the management of AF in chronic AF.
BMC Pharmacology | 2011
Norbert Jost; Attila Kristóf; Zsófia Kohajda; Tamás Szél; Zoltán Husti; István Koncz; Victor Juhász; István Baczkó; Julius Gy. Papp; András Varró; László Virág
Results Diclofenac (30 μM) decreased the amplitude of rapid (IKr) and slow (IKs) delayed rectifier and L-type calcium currents (ICa) without influencing transient outward (Ito) and inward rectifier (IK1) potassium currents. The action potential was slightly lengthened in ventricular muscle but shortened in Purkinje fibres by diclofenac (20 μM). The maximum upstroke velocity (Vmax) was decreased in both preparations. Larger repolarization lengthening was observed when repolarization reserve was impaired by previous BaCl2 application. Diclofenac (3 mg/kg) did not prolong the QTc interval, while the potassium channel blocker dofetilide (25 μg/kg) significantly lengthened QTc in anaesthetized rabbits. The combination of diclofenac and dofetilide significantly prolonged QTc. Diclofenac alone did not induce torsades de pointes ventricular tachycardia (TdP) while TdP incidence following dofetilide was 20%. However, the combination of diclofenac and dofetilide led to a significant increase in the incidence of TdP.
BMC Pharmacology | 2011
Zsófia Kohajda; Attila Kristóf; Peter Kovacs; Claudia Corici; László Virág; Viktor Juhász; Zoltán Husti; István Baczkó; András Varró; Norbert Jost
Background Atrial fibrillation (AF) is a common and severe arrhythmia, which largely affects quality of life. State-of-the-art treatment of AF still relies heavily on pharmacological modalities. Therefore, the aim of the present study was to investigate and compare the properties of three repolarizing currents which contribute to AF-induced remodeling, i.e. the transient outward (Ito), ultra-rapid delayed rectifier (IKur) and acetylcholine-sensitive potassium currents (IK, ACh ) in isolated atrial myocytes obtained from normal (SR) and tachypaced model of permanent atrial fibrillation (ATR) dogs. Methods The tachypaced atrial fibrillation model was performed in dogs. Transmembrane ionic currents were investigated by applying the whole-cell patch clamp technique at 37°C, and ECG was recorded in conscious dogs.
Current Medicinal Chemistry | 2011
Norbert Jost; Zsófia Kohajda; Attila Kristóf; Zoltán Husti; Viktor Juhász; Loránd Kiss; András Varró; László Virág; István Baczkó